[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GT201000102A - SOLID DISPERSION PRODUCT OF N-ARIL UREA-BASED DRUGS - Google Patents

SOLID DISPERSION PRODUCT OF N-ARIL UREA-BASED DRUGS

Info

Publication number
GT201000102A
GT201000102A GT201000102A GT201000102A GT201000102A GT 201000102 A GT201000102 A GT 201000102A GT 201000102 A GT201000102 A GT 201000102A GT 201000102 A GT201000102 A GT 201000102A GT 201000102 A GT201000102 A GT 201000102A
Authority
GT
Guatemala
Prior art keywords
aril
solid dispersion
urea
dispersion product
based drugs
Prior art date
Application number
GT201000102A
Other languages
Spanish (es)
Inventor
Rudolf Schroeder
Tanja Heitermann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201000102A publication Critical patent/GT201000102A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UN AGENTE CON ACTIVIDAD FARMACÉUTICA BASADO EN N-ARIL UREA QUE SE OBTIENE MEDIANTE: A) LA PREPARACIÓN DE UNA MEZCLA LÍQUIDA QUE CONTIENE AL MENOS UN AGENTE ACTIVO, AL MENOS UN AGENTE FORMADOR DE MATRIZ FARMACÉUTICAMENTE ACEPTABLE Y AL MENOS UN SOLVENTE, Y B) LA ELIMINACIÓN DE UNO O MÁS SOLVENTES DE LA MEZCLA LÍQUIDA, PARA OBTENER EL PRODUCTO DE DISPERSIÓN SÓLIDA.THIS INVENTION REFERS TO AN AGENT WITH PHARMACEUTICAL ACTIVITY BASED ON N-ARIL UREA OBTAINED THROUGH: A SOLVENT, AND B) THE ELIMINATION OF ONE OR MORE SOLVENTS OF THE LIQUID MIXTURE, TO OBTAIN THE SOLID DISPERSION PRODUCT.

GT201000102A 2007-10-19 2010-04-16 SOLID DISPERSION PRODUCT OF N-ARIL UREA-BASED DRUGS GT201000102A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99961807P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
GT201000102A true GT201000102A (en) 2012-03-12

Family

ID=40089463

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201000102A GT201000102A (en) 2007-10-19 2010-04-16 SOLID DISPERSION PRODUCT OF N-ARIL UREA-BASED DRUGS

Country Status (18)

Country Link
EP (1) EP2197425A2 (en)
JP (1) JP2011500649A (en)
KR (1) KR20100087170A (en)
CN (1) CN101827584A (en)
AU (1) AU2008313622A1 (en)
BR (1) BRPI0818340A2 (en)
CA (1) CA2699301A1 (en)
CO (1) CO6270206A2 (en)
CR (1) CR11442A (en)
DO (1) DOP2010000117A (en)
EC (1) ECSP10010183A (en)
GT (1) GT201000102A (en)
MX (1) MX2010004291A (en)
PA (1) PA8800101A1 (en)
RU (1) RU2010119929A (en)
UA (1) UA100865C2 (en)
WO (1) WO2009050291A2 (en)
ZA (1) ZA201002095B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
AR077975A1 (en) 2009-08-28 2011-10-05 Irm Llc PIRAZOL PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
NZ605434A (en) * 2010-06-09 2014-03-28 Abbvie Bahamas Ltd Solid dispersions containing kinase inhibitors
CN103917236A (en) 2011-11-11 2014-07-09 诺华股份有限公司 Method of treating proliferative disease
SG11201401260QA (en) * 2011-11-23 2014-07-30 Novartis Ag Pharmaceutical formulations
WO2014003677A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising solid dispersion particles containing tadalafil
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
CA2987867C (en) 2015-06-09 2023-06-27 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009513642A (en) * 2005-10-25 2009-04-02 アボット・ラボラトリーズ Formulation containing drug with low water solubility and method of using the same
WO2007066189A2 (en) * 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
AU2007316558A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
WO2009050291A3 (en) 2010-04-08
AU2008313622A1 (en) 2009-04-23
MX2010004291A (en) 2010-08-02
CO6270206A2 (en) 2011-04-20
JP2011500649A (en) 2011-01-06
CA2699301A1 (en) 2009-04-23
CR11442A (en) 2010-09-06
UA100865C2 (en) 2013-02-11
BRPI0818340A2 (en) 2015-04-22
EP2197425A2 (en) 2010-06-23
PA8800101A1 (en) 2009-05-15
ECSP10010183A (en) 2010-06-29
KR20100087170A (en) 2010-08-03
RU2010119929A (en) 2011-11-27
ZA201002095B (en) 2011-11-30
DOP2010000117A (en) 2010-05-15
WO2009050291A2 (en) 2009-04-23
CN101827584A (en) 2010-09-08

Similar Documents

Publication Publication Date Title
GT201000102A (en) SOLID DISPERSION PRODUCT OF N-ARIL UREA-BASED DRUGS
GT201000095A (en) SOLID DISPERSION PRODUCT CONTAINING A N-ARIL UREA-BASED COMPOUND
CL2009000393A1 (en) Pharmaceutical composition comprising a) an activatable pharmaceutical agent, b) a plasmonic active agent; Useful for the treatment of cell proliferation disorders.
CL2008000691A1 (en) COMPOUNDS DERIVED FROM DIHIDRO AND TETRAHIDRO OXAZOLOPIRIMIDINONAS REPLACED; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE FOR THE TREATMENT OF CHICHOPHRENIA, EPILEPSY, BETWEEN OTHER DISEASES.
BR112014000178A2 (en) topical compositions
CL2012003415A1 (en) Compounds derived from 2-oxo-piperidine and 1,1-dioxide-thiazine, mdm2 inhibitors; pharmaceutical composition that includes them; and its use for the treatment of cancer.
UY31673A1 (en) "UREA HETEROCYCLIC DERIVATIVES AND METHODS OF USE OF THE SAME-211"
CR20110599A (en) PHARMACEUTICALLY ACTIVE COMPOSITIONS THAT INCLUDE OXIDATIVE STRESS MODULATORS (OSM), NEW CHEMICAL ENTITIES, COMPOSITIONS AND USES
CL2011001497A1 (en) Compounds derived from heterocycles, gpr120 modulator; pharmaceutical composition; and its use for the treatment of type I, ii diabetes and metabolic syndrome.
BRPI0806531A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, THERAPEUTIC AGENT, AND USE OF THE COMPOUND.
CL2013000675A1 (en) Compounds derived from substituted pyrazolamide, with activity on pge2 / ep4; pharmaceutical composition that includes them; and its use for the treatment of multiple sclerosis and rheumatoid arthritis.
BR112014027039A2 (en) non-aqueous topical pharmaceutical formulation; use of non-aqueous pharmaceutical formulation; non-aqueous formulation; and method
WO2014059444A3 (en) Chemical engines and methods for their use, especially in the injection of highly viscous fluids
CL2007002971A1 (en) COMPOUNDS DERIVED FROM AMINOMETIL-4-IMIDAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; AND ITS USE TO TREAT DEPRESSION, ANXIETY, BIPOLAR DISORDER, AMONG OTHERS.
CL2011000064A1 (en) Process to prepare microparticles of size 10-500um that comprises contacting a mixture of biologically active material, a polymer and a specific processing aid with a supercritical fluid under temperature and pressure to penetrate and liquefy the polymer and release pressure to precipitate the microparticles.
BR112015023434A8 (en) histone deacetylase inhibiting compounds, their use and pharmaceutical composition comprising them
BRPI0908097A2 (en) use of at least one compound, peptide, and pharmaceutical formulation.
ECSP11010762A (en) TOPICAL COMPOSITION FOR THE TREATMENT OF ACTINAL KERATOSIS
CL2007003557A1 (en) COMPOUNDS DERIVED FROM NITROGEN HETEROCICLES, INHIBITORS OF THE ACTIVITY ON B-RAF; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER.
CL2014003429A1 (en) Specific compounds derived from indanesulfamide; pharmaceutical composition that includes them, useful in the treatment and epilepsy.
CL2009001215A1 (en) Pharmaceutical compositions comprising a first agent selected from the group consisting of i) an anti-inflammatory agent, ii) acetaminophen, iii) phenacetin, iv) tramadol, and a second agent; use of said compositions to treat proliferative diseases including cancer.
BRPI0717369A2 (en) COMPOUND, MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND.
CO2018001918A2 (en) Urea-based molecules as pesticides, and related intermediates, compositions and processes
BR112013020841B8 (en) Process for preparing products comprising stabilized actives and compositions comprising the same
CL2009000904A1 (en) Compounds derived from cyclohexyl sulfonamides having antagonist activity at the npy y5 receptor, pharmaceutical composition and pharmaceutical formulation comprising them.